Reyvow ® (lasmiditan) tablets CV

50 mg, 100 mg

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

REYVOW® (lasmiditan): Use With Oral Calcitonin Gene-Related Peptide Receptor Antagonists

Reyvow (lasmiditan) inhibits P-gp and BCRP in vitro. The oral CGRP antagonists, ubrogepant and rimegepant, are both P-gp and BCRP substrates. Concomitant use of lasmiditan and drugs that are P-gp or BCRP substrates should be avoided.


Detailed Information

The use of lasmiditan with oral CGRP antagonists has not been studied, and the safety and efficacy of their concomitant use is unknown. 

Potential for Drug-Drug Interactions

Lasmiditan inhibits P-gp and BCRP in vitro.1,2 Drug interaction studies between lasmiditan and P-gp or BCRP substrates have not been conducted. 

Ubrogepant and rimegepant are substrates of P-gp and BCRP.3,4

Concomitant use of lasmiditan and drugs that are P-gp or BCRP substrates should be avoided.1


The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Reyvow [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

3Ubrelvy [package insert]. Madison, NJ: Allergan; 2019.

4Nurtec [package insert]. New Haven, CT: Biohaven; 2021.


BCRP = breast cancer resistance protein

CGRP = calcitonin gene-related peptide

P-gp = P-glycoprotein

Date of Last Review: April 06, 2020

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical